The Extended Agreement Term is Until March 2026The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to…
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern TimeNEW YORK, July 12,…
Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010…
Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’sROME, July 12, 2023 (GLOBE…
SHANGHAI, China, July 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…
Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business…
AUSTIN, TX / ACCESSWIRE / July 11, 2023 / The U.S. Food and Drug Administration (FDA) recently granted Fast Track…
SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development…
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no…